pre final report, page-7

Peace, my reading between the lines is definately 1 deal this Q, possibly some the next Q but this is more elastic, leading to possible push to be cash flow positive to end of FY12 rather than calendar 12.

I thought it was interesting to note that commercial revenue was slightly lower than commercial lab costs. Without the line items in the chart of accounts it is hard to tell but this suggest that they may not be making any margin on their lab time. A bit odd. Perhaps they have put their own internal lab time into this?

Otherwise as ST says the forecast growth is going in the right direction and now with cash in bank it seems we have time on our side.